Admissions:
None
Delistings:
None
What’s baking in the oven?
Potential** Initial Public Offerings:***
Banquet Buffet****
AOTI Inc 90p £95.72m (AOTI.L)
A medical technology Company focused on the durable healing of wounds and the prevention of amputations announces its trading update for the six months ended 30 June 2025 as well as an update to FY 2025 guidance. The Company expects to report revenue for the Period of not less than $31m (H1 2024: $26.3m), representing growth of not less than 18% (H1 2024: 26.4%). In the first three months of the Period, the Company recorded revenue growth of approximately 26%. Revenue growth in the six-month period ended 31 March 2025 was approximately 37%. The Company now expects revenue growth for FY 2025 to be in the mid-teens and adjusted EBITDA margin to be low double digit. The Company expects to announce its interim results for the six months ended 30 June 2025 in September 2025. The Board is confident that the Company is well-placed to deliver on its strategic priorities and growth drivers in the medium term.
Artemis Resources Ltd 0.19p £4.69m (ARV.L)
A gold, copper, and lithium focused resource Company announced it has received firm commitments for a capital raising of A$4.75m. Artemis will issue 1,187,500,000 new shares at $0.004 per share. The issue price is a 27% discount to the 15 day Volume Weighted Average Price (VWAP). Artemis will utilise this additional funding to undertake a substantial drill program of up to 5,000m including extensional drilling and technical studies at the Carlow Gold and Copper Project, RC drilling at Titan, and exploration at Cassowary.
Creo Medical Group 12.5p £51.56m (CREO.L)
The medical device Company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients provided a trading update for the six-month period ended 30 June 2025 (H1 25). H1 25 Core Technology revenues from continuing operations were up 40% to £2.2m (H1 24: £1.6m), in line with management expectations for first half performance. The Board believes the Company is tracking on plan for 40% to 60% revenue growth for the full year, in-line with prior guidance, with a continued historical H2 weighting. Cash and cash equivalents at 30 June 2025 was £20.5m (31 December 2024: £8.7m). The Board of Creo remains confident in the outlook for 2025 and expects another year of strong growth in Core Technology.
Imaging Biometrics 0.63p £1.54m (IBAI.L)
The Company involved in quantitative imaging and novel therapeutics for CNS malignancies today announces a soft close to its Phase 1 clinical trial of oral gallium maltolate (GaM) in adult relapsed or refractory glioblastoma. The trial remains active for currently enrolled participants, with no additional patients being recruited at this time. While final internal approvals from the Medical College of Wisconsin Cancer Center are pending, the soft close enables the trial team to transition toward data consolidation, endpoint analysis, and Phase 2 protocol finalisation - key steps in advancing the development of oral GaM. IBAI is actively evaluating the feasibility of independently financing the phase 2 trial while concurrently exploring strategic partnerships. The Company will provide further updates as the trial progresses toward formal closure and data dissemination.
Kromek Group 5.45p £35.70m (KMK.L)
A global detection Company delivering solutions for the advanced imaging and detection markets announced that it has received its first contract, worth £1.7m, under the UK Government's Radiological Nuclear Detection Framework for the procurement of radiological nuclear detection equipment and supporting services for the Home Office. The total value for this contract is £1.7m, of which a significant majority is scheduled to be received in the Group's current financial year and which will contribute towards the expected revenue growth in the CBRN (chemical, biological, radiological, and nuclear) Detection segment.
Metals One 11.74p £35.16m (MET1)
A minerals exploration and development Company announced the completion of its acquisition of the Squaw Creek Claims (SQ Claims) in Carbon County, Wyoming, United States which hold the Squaw Creek Uranium Project as originally announced on 24 April 2025. The SQ Claims represent the Company's second uranium project in the U.S., and complement the recently completed acquisition of the Uravan Uranium-Vanadium Project in Colorado, as announced on 2 July 2025. The consideration comprises US$50,000 in cash and the issuance of 500,000 new ordinary shares in Metals One Plc at a price equivalent to a 5% discount to the five-day volume-weighted average price (VWAP) immediately prior to execution, being 19.0363 pence per share. The Board believes the acquisition of the SQ Claims further consolidates Metals One's position in the U.S. uranium sector, aligned with the Company's strategy to advance critical mineral assets essential to the clean energy transition.
Portmeirion Group 133.50p £18.72m (PMP.L)
The global homeware brands group today issues a trading update for the six months to 30 June 2025. Group Sales are expected to be £37.1m, up 1.3% year-on-year in the period and up 2.8% in constant currency. H1 is traditionally the Group's quieter half. Net debt on 30th June 2025 is expected to be £14.8m (prior year £13.4m), marginally higher due to much earlier shipment of product into the USA market for the Holiday and Christmas season, and the associated cost of funding tariff payments. The Company anticipates modest sales growth in H2, primarily due to short term caution on the US market. The Board anticipates the UK to be flat - low single digit growth driven by good Wax Lyrical performance, and continued improvement in South Korea and International markets. The Group expects to report its Interim results for the six months ending 30 June 2025 in late September 2025.
The Pebble Group 48.50p £77.29m (PEBB.L)
The provider of technology, products, and related services to the global promotional products industry announces, further to its Half Year Trading Update on 10 July 2025, that it is proposing to return up to £6.5m to Shareholders by way of a Tender Offer pursuant to which Qualifying Shareholders are invited to tender some, or all, or their Ordinary Shares at the Tender Price of 61 pence per Ordinary Share. The Tender Offer is for a maximum of 10,655,737 Ordinary Shares. The Tender Price represents a premium of approximately 25.8% to the closing price of 48.5 pence per Ordinary Share on the Latest Practicable Date and a premium of approximately 38.6% to the closing price of 44 pence per Ordinary Share on 2 June 2025.
Verici Dx 0.88p £2.12m (VRCI.L)
A developer of clinical diagnostics for organ transplants announced it is conducting a placing to raise a minimum of £5m at a price of 0.5 pence per new Ordinary Share. The Issue Price represents a discount of 42.9 per cent. to Verici Dx's closing mid-price on 18 July 2025. The Company is proposing a WRAP Retail Offer to new and existing shareholders for up to 100,000,000 new Ordinary Shares at the Issue Price to raise up to an additional £0.5m. The net proceeds of the fundraise will provide the Company with additional working capital to support the commercial scale up of a suite of its blood-based tests for the kidney transplant market.
Zentra Group 2.75p £1.06m (AQSE: ZNT)*
The Manchester-based residential developer and development manager announced that it has completed the transfer of its listing from the Access Segment of the Aquis Stock Exchange to the newly launched Aquis Real Asset Market (ARAM). The Company's ordinary shares began trading on ARAM at 8am today. ARAM has been developed as a dedicated platform for the listing and trading of real asset-backed securities — including equity and debt at both the company and asset level. Zentra Board has said that ARAM represents an opportunity to operate in a market that is better suited to the way the business is structured and how its developments are funded.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
